COMMENTARY
Current New Drug Development in the Japanese Pharmaceutical Industry(2)
OtsukaOtsuka has one blockbuster on the global market, the anti-schizophrenic Abilify (aripiprazole) for controlling bipolar disturbances with annual sales of US$1.36 billion with BMS in 2006. Its injectable formulation for bipolar disturbances and oral tablets for add-on therapy for major…
To read the full story
COMMENTARY
- FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
- MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
- Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
- The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
- Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





